Drug Research & Development Accelerator

Amprion’s Proprietary Prion Detection Science enables pharmaceutical companies to accelerate finding the cures.

From research, development, testing, and various stages of clinical trials, our biomarker discovery technology gives drug companies a leg-up on their competition. Speed leads to success! It’s like having a pair of night-vision goggles and laser tag in the dark, mysterious drug development territory.

Our goal is simple:

We want biomarker-targeted drugs that match the patient’s biomarker profile. This is “the cure” we’ve long wished for. With research, science, and dedication, we will achieve it.

Over the past five years, Amprion has worked with major pharmaceutical companies to develop and test drugs that target specific biomarkers for the ParkinZheimer spectrum of diseases.

Through our detection science, SAA (also known as PMCA and RT-QuIC), we are speeding through drug innovation, research, and regulatory approvals to bring cures. We enable the pharmaceutical industry to match patient samples with specific clinical trials effectively.

We enlighten, enrich, and expand drug research and development for companies domestically and abroad through biomarker science.

Connect with us if you have exciting research projects we can help accelerate! 

Get In Touch

Interested in improving the rate of success for your clinical trials? Or want to explore cutting edge ways to speed up R&D for Alzheimer’s and Parkinson’s drugs?  Reach out to us. We’d love to team up.

For the first time in history, our groundbreaking technology can track the bad actors that drive the progression of Alzheimer’s, Parkinson’s, and other dementias. Cures are on the horizon!     

Alan Alda

“I love to watch how scientists’ minds work.”

Alan Alda 

Did you know that the gene ApoE4 affects women more severely than men? Scientists are trying to understand why.